Hepatic Artery Infusion of CD34+ Cells

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE1

Study Classification

INTERVENTIONAL

Study Start Date

2002-05-31

Study Completion Date

2005-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective is to determine whether donor stem cells administered via hepatic artery infusion can produce liver cells in patients with severe hepatic dysfunction post stem cell transplantation (SCT) and the safety of this procedure. The secondary objective is to improve liver function and improve survival.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase I/II Safety and Tolerability Dose Escalation Study of Autologous Stem Cells to Patients With Liver Insufficiency

NCT00655707

Liver Disease

COMPLETED PHASE1/PHASE2

Cell Infusion Intraportal Autologous Bone Marrow Mononuclear as Enhancer of Liver Regeneration

NCT01745731

Liver Transplant Rejection

COMPLETED PHASE2

Human Umbilical Cord-mesenchymal Stem Cells Via Different Transplantation Routes in ESLD

NCT06984497

End-Stage Liver Diseases

NOT_YET_RECRUITING NA

Effect of Exosomes Derived From Red Blood Cell Units on Platelet Function and Blood Coagulation

NCT02594345

Blood Coagulation Platelet Function

COMPLETED NA

Autologous Bone Marrow Derived Stem Cells in Decompensate Cirrhotic Patients

NCT01120925

Liver Cirrhosis

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Participants in this study have received stem cell transplantation. As a result of this procedure, participants have developed severe liver dysfunction. Researchers have recently discovered that cells circulating in the blood and bone marrow are capable of forming liver cells. Before taking part in this study, women able to have children must have a negative blood pregnancy test.

Participants in this study will have donor's cells infused directly into their liver through a catheter that will be inserted through the groin. This will be done after liver disease has been diagnosed by liver biopsy. The catheter will stay in the groin for no more than 3 days. During that time, participants will be exposed to repeated x-ray exams to ensure that the catheter stays in place.

During the time that the catheter is in place, the infusion will be repeated as long as donor's cells are available. Participants will receive different drugs by vein to decrease the risk of transfusion reaction. After completing donor cell infusion, the catheter will be removed.

After participants are released from the hospital, they will have periodic evaluation of liver size. About 1 teaspoon of blood will be drawn for standard blood tests to evaluate liver function. Around Days 28 and 90, participants will have liver biopsy.

This is an investigational study. A total of 10 patients will take part in this study. All will be enrolled at UTMDACC.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stem Cell Transplantation Liver Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hepatic Artery Infusion

Donor-derived CD34+ cells administered in a total volume of 100ml via hepatic artery over 10 minutes. Cells given as a dose escalation study. First cohort of 3 patients receive 1 \* 106 CD34+ cells/kg. Next 3 patients receive 2.5 \* 106 CD34+cells/kg. Next 3 patients receive 5 \* 106 CD34+ cells/kg. Less than 1 \* 105 T cells/kg administered.

Group Type EXPERIMENTAL

Hepatic artery infusion of CD34+ cells

Intervention Type PROCEDURE

Donor's cells infused directly into liver through a groin catheter (hepatic artery).

Cobe Spectra

Intervention Type DEVICE

Mononuclear cells (MNC) collected by continuous-flow centrifugation using a blood cell separator (Cobe Spectra).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hepatic artery infusion of CD34+ cells

Donor's cells infused directly into liver through a groin catheter (hepatic artery).

Intervention Type PROCEDURE

Cobe Spectra

Mononuclear cells (MNC) collected by continuous-flow centrifugation using a blood cell separator (Cobe Spectra).

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

blood cell separator

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* SCT recipients with severe hepatic dysfunction (bilirubin equal to or greater than 5mg/dl) and histologically documented VOD.
* The original stem cell donor must be sex-mismatched, willing and able to donate G-CSF-mobilized peripheral blood stem cells.
* The patient must have complete donor chimerism.

Exclusion Criteria

* Patients who do not have at least 5 x 10\^6 donor CD34+ cells/kg available for infusion.
* Patients with graft versus host disease (GVHD).
* Patients in whom hepatic artery infusion cannot be performed because of anatomical or technical reasons.
* Patients with active hepatitis B or C.

Eligible Sex

ALL

Accepts Healthy Volunteers

No